Patents by Inventor Warren J. Scherer

Warren J. Scherer has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • NOVEL COMPOSITIONS AND METHODS FOR TREATING CUTANEOUS ULCERS AND NON-HEALING CUTANEOUS WOUNDS USING NITRIC OXIDE-DONATING PROSTAGLANDIN F-2 -ALPHA ANALOGS
    Publication number: 20210121431
    Abstract: Cutaneous ulcers and non-healing skin wounds are a route for infection and represent a source of significant morbidity and mortality for humans.
    Type: Application
    Filed: October 28, 2019
    Publication date: April 29, 2021
    Inventor: Warren J. Scherer
  • Prostaglandin F2Alpha and analogues thereof for treating atrophic cutaneous scarring
    Patent number: 10039770
    Abstract: A method of treating atrophic cutaneous scarring in humans is claimed. The method involves the topical application of a therapeutic amount of prostaglandin F2-alpha (PGF 2?) or a PGF 2? analog directly to the area of atrophic scarring.
    Type: Grant
    Filed: September 26, 2014
    Date of Patent: August 7, 2018
    Assignee: Galderma S.A.
    Inventor: Warren J. Scherer
  • Method of reducing facial flushing associated with systemic use of phosphodiesterase type 5 inhibitors
    Patent number: 9744168
    Abstract: The present invention relates to a method of reducing cutaneous facial flushing caused by systemic use of phosphodiesterase type 5 (PDE5) inhibitors by topical facial dermatological application of an effective dose of a composition comprising at least one alpha adrenergic receptor agonist.
    Type: Grant
    Filed: October 12, 2012
    Date of Patent: August 29, 2017
    Assignee: GALDERMA LABORATORIES, INC.
    Inventors: Warren J. Scherer, Arthur Clapp, Philippe Andres
  • Prostaglandin F2Alpha and Analogues Thereof for Treating Atrophic Cutaneous Scarring
    Publication number: 20160228453
    Abstract: A method of treating atrophic cutaneous scarring in humans is claimed. The method involves the topical application of a therapeutic amount of prostaglandin F2-alpha (PGF 2?) or a PGF 2? analog directly to the area of atrophic scarring.
    Type: Application
    Filed: September 26, 2014
    Publication date: August 11, 2016
    Inventor: Warren J. SCHERER
  • Method for Treating Capillary Hemangiomas
    Publication number: 20150044148
    Abstract: The invention relates to a method of treating capillary hemangiomas in a human in need thereof by topically administering an effective amount of one or more alpha-2 adrenergic receptors agonist to the site of the capillary hemangiomas on the skin of the human.
    Type: Application
    Filed: October 15, 2012
    Publication date: February 12, 2015
    Inventor: Warren J. Scherer
  • Methods of Treating Cutaneous Flushing Using Selective Alpha-2-adrenergic Receptor Agonists
    Publication number: 20150031700
    Abstract: The present invention relates to a method of treating, reducing, inhibiting, preventing and/or reversing cutaneous facial flushing caused by abnormal, endogenously-induced vasomotor instability associated with, but not limited to acne rosacea, menopause-associated hot flashes, hot flashes resulting from orchiectomy or ingestion of substances capable of inducing a cutaneous facial flushing reaction (e.g.: alcohol, chocolate, spices) by topical dermatological application of an effective dose of a composition comprising at least one ?2 adrenergic receptor agonist (such as a (2-imidazolin-2-ylamino) quinoxaline derivative such as brimonidine tartrate)and a suitable carrier.
    Type: Application
    Filed: October 14, 2014
    Publication date: January 29, 2015
    Applicant: GALDERMA LABORATORIES INC.
    Inventor: Warren J. Scherer
  • Method of Reducing Facial Flushing Associated with Systemic Use of Phosphodiesterase Type 5 Inhibitors
    Publication number: 20140343067
    Abstract: The present invention relates to a method of reducing cutaneous facial flushing caused by systemic use of phosphodiesterase type 5 (PDE5) inhibitors by topical facial dermatological application of an effective dose of a composition comprising at least one alpha adrenergic receptor agonist.
    Type: Application
    Filed: October 12, 2012
    Publication date: November 20, 2014
    Inventors: Warren J. Scherer, Arthur Clapp, Philippe Andres